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Introduction
The Top End is unique, both in the infectious agents 
that are endemic there and in its population. This 
guideline has been developed with the people, 
geography and microbial ecology of the Top End in 
mind. It may also be useful for other parts of tropical 
Australia. It aims to supplement existing protocols 
and practices for defi ned patient groups, such as 
organ transplant recipients and chemotherapy 
patients. It also aims to draw attention to patients 
who are being immunosuppressed, but for whom no 
protocol exists regarding prevention of opportunistic 
infections.
This article focuses on recommendations for the 
prevention of disseminated strongyloidiasis (DS), 
tuberculosis, melioidosis and other bacterial 
sepsis, scabies hyperinfestation and activation of 
hepatitis B virus infection, which anecdotally have 
each presented as opportunistic complications 
in immunosuppressed patients in the Northern 
Territory over recent years. These conditions 
are generally more common in the Top End than 
elsewhere in Australia. The recommendations 
are justifi ed by varying levels of evidence and 
represent a consensus guideline developed by 
local infectious diseases, renal, oncology and public 
health physicians.
This guideline is only intended to apply to people 
receiving signifi cant immunosuppression. This is 
defi ned in Box 1.1,2,3
It does not include the following patients: inhaled cort-
icosteroids, hydroxychloroquine, sulfasalazine, col-
chicine, gold, weekly methotrexate and oral courses 
of prednisone less than 14 days regardless of dose 
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Box 1. Eligible patients for the 
opportunistic infection prevention protocol
1. Anyone receiving ≥0.5mg/kg per day of pred-
nisolone or the equivalent for >14 days.
2. Anyone currently receiving cyclosporin, cyclo-
phosphamide, azathioprine, mycophenolate, 
tacrolimus or cancer chemotherapy.
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and where the frequency is less than six courses per 
year. Patients having ≥6 courses of pre dnisolone per 
year may also benefi t from the protocol.
With systemically administered steroids, the risk of 
infect ion is related to the dose of steroid and the dur-
ation of therapy as demonstrated in a meta-analysis 
of 71 controlled trials.3 The overall rate of infectious 
com plications was 12.7 per cent in steroid-treated 
patients compared to 8.0 per cent in the control 
group (relative risk 1.6). The rate of infection was 
not increased in patients receiving less than 10 mg 
per day or a cumulative dose of less than 700 mg of 
prednisone (which is roughly equivalent to 0.5mg/kg 
for 20 days). There fore a cut-off of prednisolone 
≥0.5mg/kg/day for >14 days for this protocol is 
practical. This is supported by there having been to 
date no confi rmed cases of disseminated strongyl-
oidiasis in the Top End in patients on intermittent 
pred nisolone therapy for respiratory and other 
conditions.
Each infection will be addressed in turn.
Strongyloides stercoralis
Strongyloides infestation is endemic in most remote 
communities of the Top End of the Northern Territory, 
particularly in the East Arnhem region.  A stool 
microscopy prevalence study in 1997 at Galawin`ku 
(Elcho Island, Arnhem Land) showed strongyloides 
larvae in the stool in 15 per cent of 300 people.4  In 
1991/1992, at least 3.4 per cent (68/2000) of all 
admissions to Royal Darwin Hospital (RDH) had 
strongyloides larvae detected in stool.5 During this 
12-month period, another 98 cases of strongyloidiasis 
were detected in other Top End laboratories. Reliable 
prevalence data for other Top End communities is not 
available, but the incidence of symptomatic infection 
and stool positivity seems signifi cantly lower outside 
East Arnhem. We encourage collection and analysis 
of stool prevalence data from Northern Territory 
communities outside East Arnhem to confi rm this 
impression.
The authors are aware of six cases of dissemin-
ated strongyloidiasis (including 1 death) in immuno-
suppressed patients from the Top End over the 
last 10 years, with a range of 0–2 cases per year.6 
There may also be undiagnosed cases occurring, 
as overwhelming sepsis in the absence of a micro-
biological diagnosis is relatively common at RDH. 
The reported mortality of DS is up to 87 per cent.7 
Thus, detection and treatment of infestation prior 
to immunosuppression could avoid potentially fatal 
DS. However, in immunocompetent individuals 
with chronic asymptomatic infestation, even the 
best diag nostic methods may miss the presence 
of strongyl oides. Eosino philia is usually absent 
in immuno suppressed people with strongyl oides 
hyper infestation, although it is often present before 
immuno suppression begins. In a 1993 RDH survey, 
peripheral eosinophilia was only present in 57 per 
cent of immun ocompetent patients with asympto-
matic infection.5
Direct stool examination for strongyloides larvae 
has a sensitivity of approximately 30 per cent if one 
stool is examined8 and 50 per cent for three stools.9 
One study claimed sensitivity of close to 100 per 
cent if seven stools are examined.10 This is clearly 
impractical in our setting.
Culture of stool (as opposed to direct microscopic 
exam ination) improves sensitivity, but is labour 
intensive, and poses a small risk of laboratory-
acquired infection. Agar-plate culture of a single 
stool specimen was approximately 90 per cent 
sensitive in one study.8 This takes 2–3 days and 
may not be practical for screening large numbers 
of specimens.
The utility of serology varies widely depending on 
the exact nature of the test used.7 Using an ELISA 
method, with crude extract of fi lariform larvae, 
improves sensitivity. Performance can be enhanced 
by pre-incubating the patient’s serum with Onchocerca 
antigens to eliminate non-specifi c cross-reactions 
before testing. Under the above conditions, the assay 
was 88 per cent sensitive and >90 per cent specifi c 
for the detection of strongyloides infection in a non-
endemic setting.11 Serology may remain positive for 
months to years after a successfully treated infection, 
and may cross-react with other helminth infestations, 
notably Ascaris lumbricoides. The titre does not 
reliably fall with successful eradication.12 RDH is using 
an ELISA with Strongyloides rattii as the antigen. 
We do not have good data about the sensitivity and 
specifi city of this technique in our setting, and therefore 
the above-quoted published rates may not apply.
In summary the sensitivity of current diagnostic 
methods is not suffi ciently high to be able to confi -
dently exclude chronic asymptomatic infestation in a 
patient who is about to begin immunosuppression.
Disseminated strongyloidiasis can occasionally occur 
with mild levels of immunosuppression e.g. a 65-year-
old man receiving 20 mg per day of prednisolone 
for severe chronic obstructive pulmonary disease 
(COPD) for 6 weeks.1 However, most case reports 
relating to DS in patients on prednisolone, were with 
doses around 1 mg/kg/day.2 There are also multiple 
case reports suggesting a strong association of dis-
seminated strongyloidiasis with HTLV-I infection, and 
less so with HIV infection. However, this assoc iation 
has to date not been borne out in Central Australia 
where HTLV-I infection is endemic.
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A recent review recommends empiric treatment 
(including those with negative serology and stool 
examinations) before organ transplantation in ‘high-
risk patients from endemic areas’.13
Ivermectin is very well tolerated. Repeated dosing 
has been used in the Northern Territory for crusted 
scabies for at least the last fi ve years without 
any signifi cant toxicity.14 Large-scale studies with 
regular six-monthly dosing have been conducted 
in West Africa, also without signifi cant drug toxicity 
detected.15
For the treatment of simple strongyloides infestation 
(in immunocompetent patients), a single dose of iver-
mectin seems equivalent to 2 doses of ivermectin, 
but is superior to three days of albendazole.16,17,18 Dis-
seminated strongyloidiasis, where the worm burden 
is massive, requires multiple doses of ivermectin, and 
suspected cases of DS should be discussed urgently 
with an infectious diseases specialist.
The concern for DS applies primarily to patients 
with solid organ transplants, chemotherapy for mal-
ignancy, immunosuppression for SLE and other 
auto immune disorders, and patients with severe, 
steroid dependant COPD/asthma requiring multiple 
courses of higher dose prednisolone.
The recommended management procedures to 
prevent disseminated strongyloidiasis are shown 
in Box 2.
Tuberculosis
A signifi cant proportion of the population of the 
Top End has latent infection with Mycobacterium 
tuberculosis (LTBI). Immunosuppressive medication 
greatly increases the chance of reactivation. In 
patients with HIV co-infection, the chance of devel-
oping active TB is approximately 10 per cent per 
year (compared with 10 per cent over 10–20 years 
for immunocompetent people). 
This risk is similarly increased in patients taking 
immunosuppressive medications, although this 
risk is less well defi ned. Early treatment of LTBI 
with nine months of isoniazid greatly decreases 
the chance of reactivation (by around 90%) and 
should be strongly considered in a person with 
LTBI who is to begin immunosuppression. A short 
course alternative is the combination of rifampicin 
and pyrazinamide for two months, however there 
may be an unacceptably increased risk of adverse 
reactions to the medication with this latter regime.
Box 2. Management recommendations to prevent disseminated strongyloidiasis in eligible 
patients
1. Encourage the wearing of shoes to prevent infection or decrease worm burden through reduced 
exposure to soil-borne larvae.
2. Before immunosuppression (or at initial evaluation):
– test all eligible patients with serology, eosinophil count and stool microscopy and culture. Treat all 
patients from highly endemic areas (East Arnhem), regardless of the above results, with a single dose 
of oral ivermectin 200 mcg/kg. Pregnancy test is fi rst required for all reproductive age women.
 For patients with a positive stool microscopy or culture, give a second dose of ivermectin 7 days after 
the fi rst dose. Repeat stool culture 7 days after the second dose. If still positive, discuss with the 
Infectious Diseases Unit.
– Outside of East Arnhem, only treat those with evidence of strongyloides infection.
3.  With ongoing immunosuppression:
–  In East Arnhem, repeat ivermectin every 3 months without investigation. Elsewhere, undertake sero-
logy, stool microscopy and culture for strongyloides and eosinophil count every 3 months and treat if 
positive.
4. Treat any immunosuppressed patient with unexplained pulmonary infi ltrates, fever, abdominal pain or 
septic shock with ivermectin on a day 0,1 and 7,8 regimen.
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Box 3 shows the management recommendations to 
prevent tuberculosis.
Scabies
Scabies infestation is very common in many Top End 
communities, and poses a risk of secondary bac-
terial sepsis. Infected immunosuppressed patients 
may develop a severe form of scabies, crusted 
(Norwegian) scabies,14 therefore it should be treated 
before immunosuppression. The mortality of crusted 
scabies in the Top End was up to 50 per cent within 
fi ve years of diagnosis until recent improvements 
in scabies treatment and prevention and treatment 
of secondary sepsis.19 Scabies infestation can be 
reliably detected by clinical examination.
Management recommendations to prevent scabies 
are shown in Box 4.
Hepatitis B virus
Chronic hepatitis B virus (HBV) infection is endemic 
in Top End communities with over 40 per cent of 
individuals in some communities having evidence of 
hepatitis B exposure. Endemicity, clinical impact and 
recommendations for follow up in immunocompetent 
patients from remote communities has been pub-
lished. A guideline for follow up and management 
of these non-immunosuppressed patients from 
remote communities is in use20 and should be used 
for patients on steroids alone, but not for those on 
more potent immunosuppression (Box 5). In a study 
at the RDH renal unit of patients undergoing renal 
replacement therapy, 73 of 122 Indigenous patients 
(59.8%) had evidence of hepatitis B virus exposure 
while 10 (8.2%) were HBsAg positive (Dr Nick Gray, 
Registrar in Renal Medicine, Royal Darwin Hospital, 
2001, unpublished).
Box 3. Management recommendations to 
prevent tuberculosis in eligible patients
1.  Ascertain past history of tuberculosis or lat-
ent tuberculosis infection.
–  The relevant communicable diseases clinic or 
chest clinic should be contacted to ascertain 
if the patient already has a diagnosis of LTBI 
or partially treated TB. If there is no record of 
a Mantoux, one should be performed, before 
starting immunosuppression if possible, as 
immunosuppression (particularly corticoster-
oids) will signifi cantly decrease response 
to the test. If immunosuppression must be 
commenced immediately, do a Mantoux on 
day one.
2.  Baseline two-step Mantoux testing.
–  The cutoff for a positive Mantoux prior to 
immuno suppression is 10 mm. If immuno-
suppression already exists, the cutoff is 5 mm.
–  If the initial Mantoux result is negative (<10 mm 
or <5 mm as appropriate), a second Mantoux 
should be performed 1 to 3 weeks after the 
fi rst in order to boost a false-negative fi rst 
result to a true positive value (when a person 
has LTBI, but has acquired infection many 
years before, or has anergy to tuberculin).
–  A positive Mantoux result on the initial or 
second test in the absence of active TB 
(on CXR and at clinical review) will require 
treat ment of LTBI with a 9-month course 
of isoniazid (plus pyridoxine to decrease 
neurotoxicity) or a 2-month course of rifamp-
icin and pyrazinamide.
3.  Ongoing screening if baseline two-step 
Mantoux is negative.
–  If the baseline two-step Mantoux test is neg-
ative, annual Mantoux screening for newly 
acquired LTBI should occur in those with 
continuing immunosuppression.
4.  If LTBI or past partially treated TB is identi-
fi ed, treat for this as above.
 Box 4. Management recommendations to 
prevent scabies in eligible patients
1. Treat pyoderma with a single dose of intra mus-
cular benzathine penicillin (Bicillin), 1.2 million 
units (900 mg).
2. Treat scabies with 5 per cent topical perme-
thrin at days 0 and 7. All household contacts 
should also be treated.
3. If crusted scabies is present or suspected, 
hospital admission for eradication of infection 
should be organised prior to or coincident 
with the initiation of immunosuppression.
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Rapidly progressive chronic active hepatitis may 
occur in chronically HBV-infected people who 
become immuno suppressed.21 HBsAg positive 
patients undergoing renal transplantation almost 
invari ably develop signifi cant liver dysfunction with 
deaths from fulminant hepatic failure documented.22 
Antiviral therapy is of proven benefi t in the renal 
trans plantation setting, and it is now standard 
practice that antiviral therapy be used pre-emptively 
for patients who are HBsAg positive, irrespective 
of other markers of hepatitis B viraemia or liver 
enzyme levels.23,24 Reactivation of hepatitis B 
in patients undergoing chemotherapy or potent 
immuno suppressive therapy has a mortality of 37 to 
60 per cent.25 Pre-emptive antiviral use is also now 
standard practice in liver transplant recipients, since 
studies in recent years have provided evidence of 
its effi cacy and safety.26,27
For the prevention of reactivation of hepatitis  B 
recommendations in this protocol, potent imm-
uno suppression refers to chemotherapy for malig-
nancy, organ transplantation, or potent therapy 
for autoimmune disease. This would include cyc-
lo phosphamide, azathioprine, cyclosporin, myco-
phenolate and lefl unomide but not corticosteroids 
alone. Assessment will usually include a liver 
biopsy and initiation of lamivudine and possibly 
regular hepatitis B immunoglobulin. The other and 
most newly available antiviral treatment is adefovir 
dipivoxyl. At this stage, adefovir remains reserved 
for use in those developing the YMDD (lamivudine 
resistant) mutation of the reverse transcriptase 
gene, which occurs commonly e.g. up to 27 per 
cent of liver transplant recipients on lamivudine at 
52 weeks.26 The use of antiviral medications for 
hepatitis B is generally restricted to approved liver 
clinics.
Bacterial sepsis/melioidosis
Melioidosis is more common, more severe and 
more likely to cause death in people who are 
relatively immunosuppressed.28 These data mainly 
apply to those with diabetes, heavy alcohol intake 
or chronic renal impairment, all of whom have subtle 
immune defects including poor neutrophil function. 
There have been cases of both acute melioidosis 
and relapsed melioidosis in people on therapeutic 
immunosuppression,29 and thus it is probable that 
all signifi cant therapeutic immunosuppression 
increases the probability of melioidosis occurring, 
and of it being more severe if it does occur.
Nocardia infection is uncommon, but well described 
in immunosuppressed people. Pulmonary and 
cer e bral infections are likely to occur if an immuno-
suppressed person is infected, and are diffi cult to 
treat and have a high mortality.
Skin and systemic sepsis with Staphylococcus 
aureus, Group A streptococcus and Streptococcus 
pneumoniae (among others) are very common in 
the Top End. Opportunistic infections  have been a 
signifi cant cause of morbidity and mortality in renal 
transplant patients, with a reported odds ratio for all 
infectious complications of 30 compared with non-
transplant patients.30 The majority of these infections 
are with one of the three bacteria mentioned above. 
Bacterial sepsis with S. aureus and Escherichia coli 
were the commonest causes of death in Top End 
patients with SLE from 1984–90.6 In these patients, 
staphylococcal and E. coli sepsis were particularly 
common in the setting of disease exacerbation 
and a signifi cant increase in steroid dosage with or 
without other immunosuppressive agents.
A recent review reported, ‘The use of low-dose 
trimethoprim-sulfamethoxazole in organ trans plan-
tation markedly reduces the risk of developing 
Listeria infection, Pneumocystis carinii pneumonia 
(PCP), toxoplasmosis, nocardiosis, and urinary 
tract infections’.13 It is usual after solid organ 
trans plantation to give prophylactic trimethoprim-
sulfamethoxazole for the fi rst 6–12 months post-
transplant. Its effi cacy has been confi rmed in renal 
transplant patients in a randomised controlled 
trial which found a highly signifi cant decrease in 
all bacterial infections, but not in PCP.31 In our 
setting, we recommend continuing the prophylactic 
trimethoprim-sulfamethoxazole as long as potent 
immunosuppression continues, provided no attrib-
utable signifi cant and unavoidable adverse medi-
cation reactions occur.
Box 5. Management recommendations to 
prevent reactivation of hepatitis B in eligible 
patients
–  Any HBsAg positive patient in whom 
chemo therapy for cancer or potent immuno-
suppression is planned should be referred 
to the liver clinic for assessment, preferably 
prior to therapy.
–  Non-immune patients should be vaccinated 
against hepatitis B prior to planned immuno-
suppression.
CDI Vol 27 No 4 2003 531
 Article
Prophylactic antibiotics are usually not needed with 
steroids alone. The exception to this rule is patients 
on particularly high doses (100 mg per day or more 
of prednisolone or equivalent). In the study on SLE 
in the Top End quoted previously, when steroid 
dose was intensifi ed, the incidence of serious 
opp or tunistic infections increased signifi cantly, so 
trimethoprim-sulfamethoxazole prophylaxis may be 
justi fi ed in this subgroup. This is for PCP prophylaxis, 
and also will decrease bacterial infections (including 
those from Nocardia, staphylococci, streptococci 
and gram negatives, including Burkholderia 
pseudomallei). The recommended dose is trimeth-
oprim-sulfamethoxazole one double strength tablet 
daily (160 mg/800 mg).
Varicella zoster virus (VZV) vaccination prior 
to heavy immunosuppression13 should be given 
prior to organ transplantation if the patient is not 
already immune, as recommended by the Infectious 
Diseases Society of America.13 As it is a live 
vaccine, it should NOT be given to those who are 
already immunosuppressed. 
Management recommendations to prevent melioid-
osis and bacterial sepsis are shown in Box 6.
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